Clinical trials are often described as a key step in medical research. For SPIOMET4HEALTH, they have been much more than that. They have been the central pathway through which a scientific idea could be tested responsibly, rigorously and with patients at the centre.
SPIOMET4HEALTH was created to explore a new therapeutic approach for adolescent girls and young adult women with Polycystic Ovary Syndrome (PCOS), one of the most common endocrine-metabolic disorders affecting women. PCOS can have a major impact on health, quality of life and future wellbeing, yet there is still no approved treatment that targets its underlying causes. The project set out to address this unmet need.
On International Clinical Trials Day, SPIOMET4HEALTH looks back at one of the foundations of the project: the clinical trial that has brought together patients, clinicians, researchers and partners across Europe to advance knowledge of Polycystic Ovary Syndrome.
Why clinical trials matter
Clinical trials are fundamental because they transform promising ideas into evidence. They allow researchers to ask whether an intervention is safe, whether it works, for whom it may work, and how it may affect people’s lives beyond the clinical measurements.
In SPIOMET4HEALTH, this has meant looking at PCOS from a broad perspective. The project has not only assessed biological and clinical markers, but has also incorporated lifestyle, health-related quality of life, patient-reported outcomes, treatment acceptability, safety and adherence. This holistic approach reflects a core belief of the project: improving care means understanding the condition as patients experience it. It means considering symptoms, wellbeing, daily life, future health, and the emotional and social burden that PCOS can carry.
A Phase II clinical trial is designed to evaluate whether a treatment is effective and safe in a specific group of patients after its initial safety has already been established in earlier research stages. In SPIOMET4HEALTH, the Phase II trial has involved adolescent girls and young women with PCOS across several European clinical centres, assessing not only the safety and tolerability of the SPIOMET treatment, but also its potential impact on metabolic, hormonal and reproductive health outcomes. The trial has also incorporated patient-reported outcomes and quality-of-life measures, reflecting the project’s commitment to understanding the broader experience of living with PCOS.
A European effort built with patients at the centre
The SPIOMET4HEALTH clinical trial has been carried out across multiple clinical centres in Europe, bringing together expertise from paediatric endocrinology, gynaecology, clinical trial management, health economics, patient engagement, and more fields. Such collaboration is essential in a project of this scale. It ensures that the evidence generated is not limited to one context and it reflects the European ambition behind SPIOMET4HEALTH: to contribute knowledge that may support better decision-making for PCOS care across healthcare systems.
Above all, International Clinical Trials Day is an opportunity to recognise the people who make clinical research possible: the patients. In SPIOMET4HEALTH, patients have not only participated in the clinical trial. Their perspectives have been part of the project’s design, implementation and evaluation. Patient engagement has helped shape how information is communicated, how participation is supported, and how the project understands the real-life impact of PCOS and potential future therapies.
This is why today is also a moment of gratitude. To every participant who joined the trial, attended visits, answered questionnaires, followed study procedures and shared their experience: thank you. Your contribution is at the centre of SPIOMET4HEALTH. Without you, there would be no evidence, no progress and no possibility of moving closer to better care for PCOS.
Looking ahead
Today, SPIOMET4HEALTH has entered a new and decisive phase. With the clinical trials closed since mid-2025, the project is now focused on analysing the data collected before final results can be formulated.
Until then, International Clinical Trials Day reminds us that clinical trials are not only a scientific process; they are a collective effort built on trust. They connect research with real lives and help turn unanswered questions into knowledge that may benefit future patients.